• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    5 Value Stocks To Watch In The Healthcare Sector

    1/29/24 9:44:11 AM ET
    $CALC
    $OGN
    $QNRX
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CALC alert in real time by email

    What is a Value Stock?

    A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

    Below is a list of notable value stocks in the healthcare sector:

    1. CalciMedica (NASDAQ:CALC) - P/E: 0.07
    2. Quoin Pharmaceuticals (NASDAQ:QNRX) - P/E: 2.62
    3. SCYNEXIS (NASDAQ:SCYX) - P/E: 1.26
    4. Syros Pharmaceuticals (NASDAQ:SYRS) - P/E: 8.08
    5. Organon (NYSE:OGN) - P/E: 7.34

    CalciMedica's earnings per share for Q3 sits at $-0.82, whereas in Q2, they were at -1.11. Quoin Pharmaceuticals's earnings per share for Q3 sits at $-1.95, whereas in Q2, they were at -2.13. This quarter, SCYNEXIS experienced a decrease in earnings per share, which was $2.46 in Q2 and is now $-0.04. Syros Pharmaceuticals has reported Q3 earnings per share at $-1.43, which has decreased by 10.0% compared to Q2, which was -1.3. Most recently, Organon reported earnings per share at $0.87, whereas in Q2 earnings per share sat at $1.31. Most recently, the company reported a dividend yield of 7.65%, which has increased by 2.51% from last quarter's yield of 5.14%.

    The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.

    Get the next $CALC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CALC
    $OGN
    $QNRX
    $SCYX

    CompanyDatePrice TargetRatingAnalyst
    CalciMedica Inc.
    $CALC
    1/29/2026Buy → Neutral
    H.C. Wainwright
    Organon & Co.
    $OGN
    12/9/2025$7.50Underweight
    Barclays
    Organon & Co.
    $OGN
    10/27/2025$5.00Overweight → Underweight
    Piper Sandler
    Organon & Co.
    $OGN
    5/2/2025Outperform → In-line
    Evercore ISI
    Organon & Co.
    $OGN
    9/6/2024$18.00 → $20.00Neutral → Underweight
    JP Morgan
    Organon & Co.
    $OGN
    11/3/2023$33.00 → $16.00Buy → Neutral
    Goldman
    Organon & Co.
    $OGN
    9/21/2023$28.00Overweight
    Barclays
    Organon & Co.
    $OGN
    3/16/2023$33.00Outperform
    Raymond James
    More analyst ratings

    $CALC
    $OGN
    $QNRX
    $SCYX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

    SCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a Phase 1 study and plans to report topline data in the second half of 2026 Responding to patients' need for alternatives to existing anti-fungal therapies, SCYNEXIS plans to initiate an expanded access program for SCY-247 in the first half of 2026SCYNEXIS ended Q4 2025 with cash, cash equivalents and investments of $56.3 million, resulting in a cash runway of more than two years JERSEY CITY, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneerin

    3/4/26 4:20:00 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CalciMedica Reports 2025 Financial Results and Provides Clinical Updates

    Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related toxicity with Auxora™Design of pivotal program in acute pancreatitis (AP) expected in 1H 2026JCI Insight publication of preclinical data demonstrates CM5480 as a potential differentiated therapy in pulmonary arterial hypertension (PAH); IND submission anticipated in 2027 LA JOLLA, Calif., March 3, 2026 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic

    3/3/26 7:00:00 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New Analysis of Organon's VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis

    Clinically meaningful improvements in sleep scores, as measured by subdomains of the Patient-Oriented Eczema Measure (POEM) and Dermatitis Family Impact (DFI) assessments, were observed as early as week 1 and continued through week 8 Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present results from a sub-analysis of pooled data from the Phase 3 ADORING 1 and ADORING 2 pivotal trials evaluating VTAMA cream versus vehicle at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia, Pennsylvania, on February 27, 2026. The findings show that VTAMA cream prov

    2/27/26 8:00:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALC
    $OGN
    $QNRX
    $SCYX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chair Cox Carrie Smith bought $501,755 worth of shares (65,400 units at $7.67) (SEC Form 4)

    4 - Organon & Co. (0001821825) (Issuer)

    11/13/25 4:05:10 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Langer Dennis bought $128,640 worth of ADSs (15,152 units at $8.49), increasing direct ownership by 1,515,200% to 15,153 units (SEC Form 4)

    4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    10/15/25 5:15:20 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    CHIEF BUSINESS OFFICER Roberts Eric W bought $7,675 worth of shares (2,500 units at $3.07) (SEC Form 4)

    4 - CalciMedica, Inc. (0001534133) (Issuer)

    9/22/25 9:35:04 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALC
    $OGN
    $QNRX
    $SCYX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CalciMedica downgraded by H.C. Wainwright

    H.C. Wainwright downgraded CalciMedica from Buy to Neutral

    1/29/26 7:00:08 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Organon with a new price target

    Barclays initiated coverage of Organon with a rating of Underweight and set a new price target of $7.50

    12/9/25 8:51:54 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Organon from Overweight to Underweight and set a new price target of $5.00

    10/27/25 11:23:41 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALC
    $OGN
    $QNRX
    $SCYX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for BREXAFEMME issued to SCYNEXIS, INC

    Submission status for SCYNEXIS, INC's drug BREXAFEMME (ORIG-1) with active ingredient IBREXAFUNGERP has changed to 'Approval' on 06/01/2021. Application Category: NDA, Application Number: 214900, Application Classification: Type 1 - New Molecular Entity

    6/2/21 11:20:46 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for BREXAFEMME issued to SCYNEXIS, INC

    Submission status for SCYNEXIS, INC's drug BREXAFEMME (SUPPL-1) with active ingredient IBREXAFUNGERP has changed to 'Approval' on 06/01/2021. Application Category: NDA, Application Number: 214900, Application Classification: Type 1 - New Molecular Entity

    6/2/21 9:57:42 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALC
    $OGN
    $QNRX
    $SCYX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Human Resources Officer Falcione Aaron was granted 30,522 shares and covered exercise/tax liability with 11,006 shares, increasing direct ownership by 34% to 84,109 units (SEC Form 4)

    4 - Organon & Co. (0001821825) (Issuer)

    3/3/26 7:02:48 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Walsh Matthew M was granted 54,619 shares and covered exercise/tax liability with 19,004 shares, increasing direct ownership by 25% to 180,751 units (SEC Form 4)

    4 - Organon & Co. (0001821825) (Issuer)

    3/3/26 7:01:47 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Head of Global Business Svcs Nisita Vittorio was granted 20,883 shares and covered exercise/tax liability with 7,785 shares, increasing direct ownership by 33% to 58,284 units (SEC Form 4)

    4 - Organon & Co. (0001821825) (Issuer)

    3/3/26 7:00:32 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALC
    $OGN
    $QNRX
    $SCYX
    SEC Filings

    View All

    SEC Form 10-K filed by SCYNEXIS Inc.

    10-K - SCYNEXIS INC (0001178253) (Filer)

    3/4/26 4:01:59 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by CalciMedica Inc.

    S-3 - CalciMedica, Inc. (0001534133) (Filer)

    3/3/26 4:54:00 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by CalciMedica Inc.

    10-K - CalciMedica, Inc. (0001534133) (Filer)

    3/3/26 4:05:57 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALC
    $OGN
    $QNRX
    $SCYX
    Leadership Updates

    Live Leadership Updates

    View All

    CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

    SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanism, announces the appointment of Eric Francois to the Company's Board of Directors. "Eric's decades of financial, transactional and operational experience will make an immediate impact to CERo's board of directors," said Chris Ehrlich, Company Chairman and Chief Executive Officer. "Furthermore, his expertise in capital raising, M&A, and business development will be an impactful addition at this stage of our development." Mr. Francois is an executive with over 25

    2/17/26 8:00:00 AM ET
    $CERO
    $CRVO
    $SCYX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation

    Organon (NYSE:OGN) ("Organon" or "the company") today announced that its Board of Directors has appointed the Company's Executive Vice President and Head of Manufacturing & Supply, Joseph Morrissey, Interim Chief Executive Officer. Board Chair Carrie S. Cox will also take on additional responsibilities on an interim basis as Executive Chair to support Mr. Morrissey in his new role. Director Robert Essner will assume the role of Lead Independent Director. These appointments follow the resignation of Kevin Ali as Chief Executive Officer and member of the Board in connection with the Audit Committee investigation described below. Mr. Ali has agreed that he will not be entitled to severance o

    10/27/25 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy

    ASHBURN, Va., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the appointment of its new Chief Financial Officer as the Company advances its lead product candidate, QRX003, through pivotal clinical studies and prepares for potential commercialization. Quoin has appointed Sally Lawlor, BCL, FCA, as its new Chief Financial Officer, effective immediately. Ms. Lawlor is an accomplished finance executive with over 20 years of experience in financial leadership roles in public and private companies as well as a Big Four accounting fir

    8/18/25 8:30:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $CALC
    $OGN
    $QNRX
    $SCYX
    Financials

    Live finance-specific insights

    View All

    Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025

    Full year 2025 revenue of $6.2 billion, down 3% on both an as-reported basis and at constant currency Full year 2025 diluted earnings per share of $0.72 and non-GAAP Adjusted diluted earnings per share of $3.66 Full year 2025 Adjusted EBITDA of $1.91 billion inclusive of $6 million of IPR&D, representing a 30.7% Adjusted EBITDA margin The company expects to deliver approximately $6.2 billion of revenue and approximately $1.9 billion of Adjusted EBITDA for the full year 2026, both measures in-line with full year 2025 performance. Organon (NYSE:OGN) today announced its results for the fourth quarter and full year ended December 31, 2025. "In 2025 we took action that demonstrate

    2/12/26 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026

    Organon (NYSE:OGN), a global healthcare company with a primary focus on women's health, will release its fourth quarter and full year 2025 financial results on February 12, 2026, prior to the company's webcast and conference call scheduled for 8:30 a.m. ET. IPR&D and Milestones Organon does not currently expect to record any milestone expense in the fourth quarter of 2025. Organon's fourth quarter and full year 2025 results have not been finalized and are subject to the company's quarterly financial statement closing procedures. There can be no assurance that actual results will not differ from the preliminary estimates described herein. Accessing Fourth Quarter and Full Year 2025 F

    1/29/26 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon Reports Results for the Third Quarter Ended September 30, 2025

    Third quarter 2025 revenue of $1.602 billion, up 1% as-reported and down 1% excluding the impact of foreign currency Third quarter 2025 diluted earnings per share of $0.61 and non-GAAP Adjusted diluted earnings per share of $1.01 Third quarter 2025 net income of $160 million and Adjusted EBITDA (non-GAAP) of $518 million, representing an Adjusted EBITDA margin of 32.3% Revenue guidance range for full year 2025 lowered to $6.200 billion to $6.250 billion; Adjusted EBITDA margin guidance lowered to ~31.0% Organon (NYSE:OGN) today announced its results for the third quarter ended September 30, 2025. "I am humbled to be working alongside our talented team during this pivotal time

    11/10/25 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALC
    $OGN
    $QNRX
    $SCYX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by CalciMedica Inc.

    SC 13D - CalciMedica, Inc. (0001534133) (Subject)

    11/26/24 6:03:55 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd.

    SC 13G/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)

    11/14/24 7:23:29 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by SCYNEXIS Inc.

    SC 13G/A - SCYNEXIS INC (0001178253) (Subject)

    11/14/24 7:07:26 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care